List of Excipients in API diazoxide
✉ Email this page to a colleague
Excipients in NDA-approved (novel) drugs containing diazoxide
| Company | Tradename | Ingredient | NDC | Excipient | Potential Generic Entry |
|---|---|---|---|---|---|
| Teva Pharmaceuticals USA Inc | PROGLYCEM | diazoxide | 0575-6200 | ALCOHOL | |
| Teva Pharmaceuticals USA Inc | PROGLYCEM | diazoxide | 0575-6200 | CARBOXYMETHYLCELLULOSE SODIUM | |
| Teva Pharmaceuticals USA Inc | PROGLYCEM | diazoxide | 0575-6200 | HYDROCHLORIC ACID | |
| Teva Pharmaceuticals USA Inc | PROGLYCEM | diazoxide | 0575-6200 | MAGNESIUM ALUMINUM SILICATE | |
| >Company | >Tradename | >Ingredient | >NDC | >Excipient | >Potential Generic Entry |
Excipients in ANDA-approved (generic) drugs containing diazoxide
| Company | Ingredient | NDC | Excipient |
|---|---|---|---|
| Par Pharmaceutical Inc | diazoxide | 0254-1010 | ALCOHOL |
| Par Pharmaceutical Inc | diazoxide | 0254-1010 | CARBOXYMETHYLCELLULOSE SODIUM |
| Par Pharmaceutical Inc | diazoxide | 0254-1010 | FD&C RED NO. 40 |
| Par Pharmaceutical Inc | diazoxide | 0254-1010 | FD&C YELLOW NO. 6 |
| >Company | >Ingredient | >NDC | >Excipient |
Detailed excipient profiles for diazoxide
Excipient focus: ALCOHOL
diazoxide drug variants containing ALCOHOL
| Company | Ingredient | NDC |
|---|---|---|
| Par Pharmaceutical Inc | diazoxide | 0254-1010 |
| Teva Pharmaceuticals USA Inc | diazoxide | 0575-6200 |
| e5 Pharma LLC | diazoxide | 13517-100 |
| TriRx Huntsville Pharmaceutical Services LLC | diazoxide oral suspension | 80432-057 |
| >Company | >Ingredient | >NDC |
diazoxide drug variants not containing ALCOHOL
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: CARBOXYMETHYLCELLULOSE SODIUM
diazoxide drug variants containing CARBOXYMETHYLCELLULOSE SODIUM
| Company | Ingredient | NDC |
|---|---|---|
| Par Pharmaceutical Inc | diazoxide | 0254-1010 |
| Teva Pharmaceuticals USA Inc | diazoxide | 0575-6200 |
| e5 Pharma LLC | diazoxide | 13517-100 |
| TriRx Huntsville Pharmaceutical Services LLC | diazoxide oral suspension | 80432-057 |
| >Company | >Ingredient | >NDC |
diazoxide drug variants not containing CARBOXYMETHYLCELLULOSE SODIUM
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: FD&C RED NO. 40
diazoxide drug variants containing FD&C RED NO. 40
| Company | Ingredient | NDC |
|---|---|---|
| Par Pharmaceutical Inc | diazoxide | 0254-1010 |
| >Company | >Ingredient | >NDC |
diazoxide drug variants not containing FD&C RED NO. 40
| Company | Ingredient | NDC |
|---|---|---|
| Teva Pharmaceuticals USA Inc | diazoxide | 0575-6200 |
| e5 Pharma LLC | diazoxide | 13517-100 |
| TriRx Huntsville Pharmaceutical Services LLC | diazoxide oral suspension | 80432-057 |
| >Company | >Ingredient | >NDC |
Excipient focus: FD&C YELLOW NO. 6
diazoxide drug variants containing FD&C YELLOW NO. 6
| Company | Ingredient | NDC |
|---|---|---|
| Par Pharmaceutical Inc | diazoxide | 0254-1010 |
| >Company | >Ingredient | >NDC |
diazoxide drug variants not containing FD&C YELLOW NO. 6
| Company | Ingredient | NDC |
|---|---|---|
| Teva Pharmaceuticals USA Inc | diazoxide | 0575-6200 |
| e5 Pharma LLC | diazoxide | 13517-100 |
| TriRx Huntsville Pharmaceutical Services LLC | diazoxide oral suspension | 80432-057 |
| >Company | >Ingredient | >NDC |
Excipient focus: HYDROCHLORIC ACID
diazoxide drug variants containing HYDROCHLORIC ACID
| Company | Ingredient | NDC |
|---|---|---|
| Par Pharmaceutical Inc | diazoxide | 0254-1010 |
| Teva Pharmaceuticals USA Inc | diazoxide | 0575-6200 |
| e5 Pharma LLC | diazoxide | 13517-100 |
| TriRx Huntsville Pharmaceutical Services LLC | diazoxide oral suspension | 80432-057 |
| >Company | >Ingredient | >NDC |
diazoxide drug variants not containing HYDROCHLORIC ACID
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: MAGNESIUM ALUMINUM SILICATE
diazoxide drug variants containing MAGNESIUM ALUMINUM SILICATE
| Company | Ingredient | NDC |
|---|---|---|
| Par Pharmaceutical Inc | diazoxide | 0254-1010 |
| Teva Pharmaceuticals USA Inc | diazoxide | 0575-6200 |
| e5 Pharma LLC | diazoxide | 13517-100 |
| TriRx Huntsville Pharmaceutical Services LLC | diazoxide oral suspension | 80432-057 |
| >Company | >Ingredient | >NDC |
diazoxide drug variants not containing MAGNESIUM ALUMINUM SILICATE
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: METHYLPARABEN
diazoxide drug variants containing METHYLPARABEN
| Company | Ingredient | NDC |
|---|---|---|
| Par Pharmaceutical Inc | diazoxide | 0254-1010 |
| Teva Pharmaceuticals USA Inc | diazoxide | 0575-6200 |
| e5 Pharma LLC | diazoxide | 13517-100 |
| TriRx Huntsville Pharmaceutical Services LLC | diazoxide oral suspension | 80432-057 |
| >Company | >Ingredient | >NDC |
diazoxide drug variants not containing METHYLPARABEN
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: POLOXAMER 188
diazoxide drug variants containing POLOXAMER 188
| Company | Ingredient | NDC |
|---|---|---|
| Par Pharmaceutical Inc | diazoxide | 0254-1010 |
| Teva Pharmaceuticals USA Inc | diazoxide | 0575-6200 |
| e5 Pharma LLC | diazoxide | 13517-100 |
| >Company | >Ingredient | >NDC |
diazoxide drug variants not containing POLOXAMER 188
| Company | Ingredient | NDC |
|---|---|---|
| TriRx Huntsville Pharmaceutical Services LLC | diazoxide oral suspension | 80432-057 |
| >Company | >Ingredient | >NDC |
Excipient focus: PROPYLENE GLYCOL
diazoxide drug variants containing PROPYLENE GLYCOL
| Company | Ingredient | NDC |
|---|---|---|
| Par Pharmaceutical Inc | diazoxide | 0254-1010 |
| Teva Pharmaceuticals USA Inc | diazoxide | 0575-6200 |
| e5 Pharma LLC | diazoxide | 13517-100 |
| TriRx Huntsville Pharmaceutical Services LLC | diazoxide oral suspension | 80432-057 |
| >Company | >Ingredient | >NDC |
diazoxide drug variants not containing PROPYLENE GLYCOL
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: PROPYLENE OXIDE
diazoxide drug variants containing PROPYLENE OXIDE
| Company | Ingredient | NDC |
|---|---|---|
| TriRx Huntsville Pharmaceutical Services LLC | diazoxide oral suspension | 80432-057 |
| >Company | >Ingredient | >NDC |
diazoxide drug variants not containing PROPYLENE OXIDE
| Company | Ingredient | NDC |
|---|---|---|
| Par Pharmaceutical Inc | diazoxide | 0254-1010 |
| Teva Pharmaceuticals USA Inc | diazoxide | 0575-6200 |
| e5 Pharma LLC | diazoxide | 13517-100 |
| >Company | >Ingredient | >NDC |
Excipient focus: PROPYLPARABEN
diazoxide drug variants containing PROPYLPARABEN
| Company | Ingredient | NDC |
|---|---|---|
| Par Pharmaceutical Inc | diazoxide | 0254-1010 |
| Teva Pharmaceuticals USA Inc | diazoxide | 0575-6200 |
| e5 Pharma LLC | diazoxide | 13517-100 |
| TriRx Huntsville Pharmaceutical Services LLC | diazoxide oral suspension | 80432-057 |
| >Company | >Ingredient | >NDC |
diazoxide drug variants not containing PROPYLPARABEN
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: SODIUM BENZOATE
diazoxide drug variants containing SODIUM BENZOATE
| Company | Ingredient | NDC |
|---|---|---|
| Par Pharmaceutical Inc | diazoxide | 0254-1010 |
| Teva Pharmaceuticals USA Inc | diazoxide | 0575-6200 |
| e5 Pharma LLC | diazoxide | 13517-100 |
| TriRx Huntsville Pharmaceutical Services LLC | diazoxide oral suspension | 80432-057 |
| >Company | >Ingredient | >NDC |
diazoxide drug variants not containing SODIUM BENZOATE
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: SODIUM HYDROXIDE
diazoxide drug variants containing SODIUM HYDROXIDE
| Company | Ingredient | NDC |
|---|---|---|
| Teva Pharmaceuticals USA Inc | diazoxide | 0575-6200 |
| e5 Pharma LLC | diazoxide | 13517-100 |
| >Company | >Ingredient | >NDC |
diazoxide drug variants not containing SODIUM HYDROXIDE
| Company | Ingredient | NDC |
|---|---|---|
| Par Pharmaceutical Inc | diazoxide | 0254-1010 |
| TriRx Huntsville Pharmaceutical Services LLC | diazoxide oral suspension | 80432-057 |
| >Company | >Ingredient | >NDC |
Excipient focus: SORBITOL
diazoxide drug variants containing SORBITOL
| Company | Ingredient | NDC |
|---|---|---|
| Par Pharmaceutical Inc | diazoxide | 0254-1010 |
| Teva Pharmaceuticals USA Inc | diazoxide | 0575-6200 |
| e5 Pharma LLC | diazoxide | 13517-100 |
| >Company | >Ingredient | >NDC |
diazoxide drug variants not containing SORBITOL
| Company | Ingredient | NDC |
|---|---|---|
| TriRx Huntsville Pharmaceutical Services LLC | diazoxide oral suspension | 80432-057 |
| >Company | >Ingredient | >NDC |
Excipient focus: SORBITOL SOLUTION 70%
diazoxide drug variants containing SORBITOL SOLUTION 70%
| Company | Ingredient | NDC |
|---|---|---|
| TriRx Huntsville Pharmaceutical Services LLC | diazoxide oral suspension | 80432-057 |
| >Company | >Ingredient | >NDC |
diazoxide drug variants not containing SORBITOL SOLUTION 70%
| Company | Ingredient | NDC |
|---|---|---|
| Par Pharmaceutical Inc | diazoxide | 0254-1010 |
| Teva Pharmaceuticals USA Inc | diazoxide | 0575-6200 |
| e5 Pharma LLC | diazoxide | 13517-100 |
| >Company | >Ingredient | >NDC |
Excipient focus: WATER
diazoxide drug variants containing WATER
| Company | Ingredient | NDC |
|---|---|---|
| Par Pharmaceutical Inc | diazoxide | 0254-1010 |
| Teva Pharmaceuticals USA Inc | diazoxide | 0575-6200 |
| e5 Pharma LLC | diazoxide | 13517-100 |
| >Company | >Ingredient | >NDC |
diazoxide drug variants not containing WATER
| Company | Ingredient | NDC |
|---|---|---|
| TriRx Huntsville Pharmaceutical Services LLC | diazoxide oral suspension | 80432-057 |
| >Company | >Ingredient | >NDC |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
© Copyright 2002-2024 thinkBiotech LLC
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Generic Entry Opportunies 2024 - 2025
NCE-1 Patent Challenge Dates 2024 - 2025
Trigger-based marketing for the life sciences
Get DrugPatentWatch Business Intelligence Reports at Amazon.com
DrugChatter - AI-based answers to questions about drugs
RxJam - HIPAA-ready chat for life sciences
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Generic Entry Opportunies 2024 - 2025
NCE-1 Patent Challenge Dates 2024 - 2025
Trigger-based marketing for the life sciences
Get DrugPatentWatch Business Intelligence Reports at Amazon.com
DrugChatter - AI-based answers to questions about drugs
RxJam - HIPAA-ready chat for life sciences
Preferred Citation:
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2024, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch
Links
Follow DrugPatentWatch:
